stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −67.6%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Free cash flow margin
CG Oncology, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was −3,068.0%, up 211.2 percentage points from fiscal 2025 (−3,279.2%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −3,279.2% | 3,652.05 |
| FY2024 | −6,931.3% | 15,460.41 |
| FY2023 | −22,391.7% | (6,780.15) |
| FY2022 | −15,611.5% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 31.4% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| PTCT PTC Therapeutics, Inc. compare | −22.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −46.0% |
| CGON CG Oncology, Inc. | −2,879.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement